Andisheh Choupani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andisheh Choupani has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bekir Bediz
Faculty of Engineering and Natural Sciences, Mechatronics Engineering Program, Sabanci University, Istanbul, Türkiye
1 shared publication Busra Tugba Camic
SUNUM Nanotechnology Research and Application Center, Sabanci University, Istanbul, Türkiye
1 shared publication- Eda Ciftci
Department of Bioengineering Graduate School of Science and Engineering, Hacettepe University, Beytepe Ankara Türkiye
1 shared publication Elif Sevval Temucin
Mechatronics Engineering Program, Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Türkiye
1 shared publication- Feray Bakan
Nanotechnology Research and Application Center Sabancı University Istanbul Türkiye
1 shared publication - Feza Korkusuz
Department of Sports Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Türkiye
1 shared publication
Latest Publications
- 12 September 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 36 (1) , 64-85
Design of poly(vinyl pyrrolidone) and poly(ethylene glycol) microneedle arrays for delivering glycosaminoglycan, chondroitin sulfate, and hyaluronic acid
Diabetes mellitus (DM) is a multifactorial life-threatening endocrine disease characterized by abnormalities in glucose metabolism. It is a chronic metabolic disease that involves multiple enzymes such as alpha-amylase and alpha-glucosidases. Inhibition of these enzymes has been identified as a promising method for managing diabetes, and researchers are currently focusing on discovering novel alpha-amylase and alpha-glucosidase inhibitors for diabetes therapy. Hence, we have selected 12 bioactive compounds from the Momordica charantia (MC) plant and performed a virtual screening and molecular dynamics investigation to identify natural inhibitors of alpha-amylase and alpha-glucosidases. Our in silico result revealed that phytocompound Rutin showed the highest binding affinity against alpha-amylase (1HNY) enzymes at (-11.68 kcal/mol), followed by Karaviloside II (-9.39), Momordicoside F (-9.19), Campesterol (-9.11. While docking against alpha-glucosidases (4J5T), Rutin again showed the greatest binding affinity (-11.93 kcal/mol), followed by Momordicine (-9.89), and Campesterol (-8.99). Molecular dynamics (MD) simulation research is currently the gold standard for drug design and discovery. Consequently, we conducted simulations of 100 nanoseconds (ns) to assess the stability of protein-ligand complexes based on parameters like RMSD, RMSF, RG, PCA, and FEL. The significance of our findings indicates that rutin from MC might serve as an effective natural therapeutic agent for diabetes management due to its strongest binding affinities with alpha-amylase and alpha-glucosidase enzymes. Further research in animals and humans is essential to validate the efficacy of these drug molecules.
- 12 September 2024
- Published by Taylor & Francis in Journal of Biomaterials Science, Polymer Edition
- Vol. 36 (1) , 64-85
Design of poly(vinyl pyrrolidone) and poly(ethylene glycol) microneedle arrays for delivering glycosaminoglycan, chondroitin sulfate, and hyaluronic acid
Diabetes mellitus (DM) is a multifactorial life-threatening endocrine disease characterized by abnormalities in glucose metabolism. It is a chronic metabolic disease that involves multiple enzymes such as alpha-amylase and alpha-glucosidases. Inhibition of these enzymes has been identified as a promising method for managing diabetes, and researchers are currently focusing on discovering novel alpha-amylase and alpha-glucosidase inhibitors for diabetes therapy. Hence, we have selected 12 bioactive compounds from the Momordica charantia (MC) plant and performed a virtual screening and molecular dynamics investigation to identify natural inhibitors of alpha-amylase and alpha-glucosidases. Our in silico result revealed that phytocompound Rutin showed the highest binding affinity against alpha-amylase (1HNY) enzymes at (-11.68 kcal/mol), followed by Karaviloside II (-9.39), Momordicoside F (-9.19), Campesterol (-9.11. While docking against alpha-glucosidases (4J5T), Rutin again showed the greatest binding affinity (-11.93 kcal/mol), followed by Momordicine (-9.89), and Campesterol (-8.99). Molecular dynamics (MD) simulation research is currently the gold standard for drug design and discovery. Consequently, we conducted simulations of 100 nanoseconds (ns) to assess the stability of protein-ligand complexes based on parameters like RMSD, RMSF, RG, PCA, and FEL. The significance of our findings indicates that rutin from MC might serve as an effective natural therapeutic agent for diabetes management due to its strongest binding affinities with alpha-amylase and alpha-glucosidase enzymes. Further research in animals and humans is essential to validate the efficacy of these drug molecules.